Drug Pipeline Update: January 2022 - Prime Therapeutics LLC

This monthly pipeline wrap up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

January 2022 Drug PIpeline Update

January 2022 Specialty Drug Pipeline Update

About Prime Therapeutics

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization serving health plans, employers and government programs. Prime is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Magellan Rx Management LLC, a Prime Therapeutics LLC Company, is a pioneer in specialty and medical drug management and a leader in serving public sector state government programs. Together Prime and Magellan Rx provide a wide range of clients with solutions that bridge the distance between medical and pharmacy management. For more information visit primetherapeutics.com and magellanrx.com or follow us on X (Twitter) at @Prime_PBM and @Magellan_Rx.

Related news

Perspectives

August 28, 2024

Clinical News: August 2024

Your monthly source for drug information highlights

Perspectives

August 28, 2024

Drug Approvals Monthly Update: August 2024

This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals…

Perspectives

August 27, 2024

Expert Clinical Network Insights: August 2024

A look into our Expert Clinical Network (ECN) — part of Prime/MRx’s value-based approach to medical and pharmacy benefit management that offers access to more than 175 national and world-renowned key opinion leaders in multiple disease categories who provide expertise on challenging prior authorization case reviews, peer-to-peer discussions, drug policy development and formulary guidance

View all news